Treating Pain in Sickle Cell Disease with Opioids: Clinical Advances, Ethical Pitfalls

Journal of Law, Medicine and Ethics 42 (2):139-146 (2014)
  Copy   BIBTEX

Abstract

Sickle cell disease is an autosomal recessive hemoglobinopathy found mainly in populations of African and Mediterranean descent, including approximately 100,000 Americans. It is also very common in Spanish-speaking regions of Central America, South America, and parts of the Caribbean, in Saudi Arabia, and in India and Sri Lanka. The disorder is characterized most commonly by lifelong recurrent unpredictable vaso-occlusive pain that may be disabling, and by chronic tissue damage and organ dysfunction. There are several genotypes of the disease. Although SCD pain frequency generally varies between genotypes, it also varies between subjects even within genotype. It may worsen from childhood to adulthood. It may vary by gender. Its location, timing, and severity may be unpredictable.Until recently, pain in SCD had been characterized as episodes that were acute, periodic, and relatively rare. Crises were viewed as usually associated with hospitalization. Many patients utilized hospital or emergency care for pain once per year or less, so painful episodes in SCD were called vaso-occlusive “crises.”

Links

PhilArchive



    Upload a copy of this work     Papers currently archived: 91,219

External links

Setup an account with your affiliations in order to access resources via your University's proxy server

Through your library

Similar books and articles

Pain, Chronic Pain, and Sickle Cell Chronic Pain.Ron Amundson - 2013 - American Journal of Bioethics 13 (4):14 - 16.
Case Study: Pain and Sickle Cell Anemia.B. A. Rich - 2001 - Hastings Center Report 31 (3):29.

Analytics

Added to PP
2016-02-04

Downloads
13 (#978,482)

6 months
3 (#902,269)

Historical graph of downloads
How can I increase my downloads?

Citations of this work

Add more citations

References found in this work

No references found.

Add more references